Bills › 2025-26
HB 1725: Biosimilar medicines
Data last updated: bill actions through Aug 23, 2026 · lobbyist reports through Sep 30, 2026 (read Oct 14, 2026)
Increasing access to biosimilar medicines.
- Prime sponsor
- My-Linh Thai
- Introduced
- Jan 30, 2025
- Status
- By resolution, reintroduced and retained in present status. (Jan 12, 2026)
- The Legislature's page
- HB 1725 on leg.wa.gov
Floor votes
No floor roll call on file (it didn't pass a chamber, or it was decided without one).
Who lobbied on it 7
| Employer | Lobbyists | To 2026 candidates |
|---|---|---|
| AMGEN INC | 1 | — |
| Association for Accessible Medicines | 1 | — |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 1 | — |
| Elevance Health, and its Affiliates | 1 | $26,400 |
| GENENTECH (contracted through KATHRYN KOLAN) | 1 | — |
| JOHNSON & JOHNSON SERVICES, INC. | 1 | $3,600 |
| PHARMACEUTICAL RSRCH/MFG OF AMERICA | 1 | — |
Lobbying reports name a bill number, not a position on it or a version of it. Money: what each employer (as a donor to two or more 2026 candidates) gave to the 2026 campaigns of the members who voted yea or nay on the bill's latest final passage in each chamber.